Paxalisib it broadly recognised as remarkable Increasing efficacy by +60% on the current standard of care... in GBM the primary condition of focus
Kazia identified a shelved molecule at the storied cancer drug development company, Genentech.
In fact, Genentech has been so successful at therapeutic development, when Roche Holdings took them over, it chose to leave it completely intact so as not to destroy Genentech’s culture of success.
Kazia felt there was a lot to like about the drug, named GDC-0084 at the time, and we concurred.
Specifically:
The science behind paxalisib was outstanding,
KZA Price at posting:
80.3¢ Sentiment: Buy Disclosure: Held
